reports
Press Release: Sanofi and Novavax announce co-exclusive licensing agre...
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with ...
Communiqué de presse : Sanofi et Novavax concluent un accord de licenc...
Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 L’accord, qui combinera la puissance commerciale des deux entreprises, permettra aux patients de bénéficier à partir de 2025 d’un meilleur accès à un vaccin adjuvanté à base de protéines, non-ARNm, contre la COVID-19 Accélération du ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by...
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
BMW BAYERISCHE MOTOREN WERKE AG
G1A GEA GROUP AG
PUM PUMA SE
AFX CARL ZEISS MEDITEC AG
UTDI UNITED INTERNET AG
ALO ALSTOM SA
ELE ENDESA S.A.
GEBN GEBERIT AG
RWE RWE AG
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
RY4C RYANAIR HOLDINGS PLC
RTLL RTL GROUP S.A.
SIX2 SIXT SE
BC8 BECHTLE AG
AMS AMADEUS IT GROUP SA CLASS A
UCG UNICREDIT S.P.A.
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
RACE FERRARI NV
ABI ANHEUSER-BUSCH INBEV SA/NV
LDO LEONARDO SPA
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
KBX KNORR-BREMSE AG
CPR DAVIDE CAMPARI-MILANO N.V.
ENR SIEMENS ENERGY AG
UN0 UNIPER SE
- Damien Choplain
- Martial Descoutures
AstraZeneca : A consensus that leaves little room for surprising guida...
>The premium can be justified by short-term growth and a well-stocked pipeline - AZN certainly benefits from: i/ attractive short-term core EPS growth for 2023-2027, up 11.5% (+12.7% expected this year), and undoubtedly the most well-stocked pipeline in the industry. These elements partly justify the market premium for its 2025 P/E (+43% vs sector median), leading to a 2023-2027 PEG of 1.6x vs 1.3x for the sector. However, this growth should be more timorous in 2...
- Damien Choplain
- Martial Descoutures
AstraZeneca : Un consensus qui ne laisse que peu de place à une guidan...
>Une prime qui se justifie par une croissance CT et un pipeline exhaustif - AZN bénéficie sans nulle doute i/ d’une croissance CT attractive Core BPA 2023-2027 en hausse de 11.5% (+12.7% att cette année) et d’un pipeline certainement le plus exhaustif de l’industrie. Ces aspects justifient en partie la prime octroyée par le marché en termes de PE 25e (+43% vs médiane sectorielle) conduisant à un PEG 23/27e de 1.6x vs 1.3x pour le secteur. En revanche cette croiss...
Trading in Novo Nordisk shares by board members, executives and associ...
Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated perso...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the programme is to reduce the company’s share capital and to meet o...
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo ...
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume we...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by...
- Dominic Rose
- Naresh Chouhan
Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)
This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...
- ABGSC Healthcare Research
- Morten Larsen
- Damien Choplain
- Martial Descoutures
Novo Nordisk : Diabetes franchise leading the way
>Insulin business in the spotlight - Novo Nordisk’s Q1 2024 results, reported this morning, beat expectations for revenues and margins: +2% ahead of expectations for the top line (DKK 65.5bn, +24% cc) and 9% better for EBIT (DKK 31.9bn, +30% cc). The GLP-1 franchise, driven by Ozempic (+65% cc), is keeping up the pace, with an increase in market share in its diabetes franchise and positive volume momentum (6% growth in GLP-1 prescriptions). But this release was m...
- Konrad Zomer
- Thomas Zlowodzki
LHA DEUTSCHE LUFTHANSA AG
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
DBK DEUTSCHE BANK AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
TEP TELEPERFORMANCE SE
WKL WOLTERS KLUWER NV
REE RED ELECTRICA CORP. SA
ORSTED ORSTED
GN GN STORE NORD A/S
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
NEM NEMETSCHEK SE
RAA RATIONAL AG
AENA AENA SME SA
CABK CAIXABANK SA
WLN WORLDLINE SA
INGA ING GROEP NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STLA STELLANTIS N.V.
SHEL SHELL PLC
GSK GSK PLC
DSFIR KONINKLIJKE DSM N.V.
NOVO B NOVO NORDISK A/S
- Konrad Zomer
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/02/2024
We are removing GALP from our ODDO BHF European Large Caps list. The stock has chalked up a performance of +31.3% since its inclusion in the list on 20 March. Our analyst is adopting today a Neutral recommendation (vs Outperform) on the stock. - ...
LHA DEUTSCHE LUFTHANSA AG
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
DBK DEUTSCHE BANK AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
TEP TELEPERFORMANCE SE
WKL WOLTERS KLUWER NV
REE RED ELECTRICA CORP. SA
ORSTED ORSTED
GN GN STORE NORD A/S
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
NEM NEMETSCHEK SE
RAA RATIONAL AG
AENA AENA SME SA
CABK CAIXABANK SA
WLN WORLDLINE SA
INGA ING GROEP NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STLA STELLANTIS N.V.
SHEL SHELL PLC
GSK GSK PLC
DSFIR KONINKLIJKE DSM N.V.
NOVO B NOVO NORDISK A/S
- Damien Choplain
- Martial Descoutures
Novo Nordisk : La franchise Diabète mène la danse
>L’insuline à l’honneur - Novo Nordisk publie ce matin ses résultats du T1 2024 qui se révèlent au-dessus des attentes au niveau des ventes et de la marge : +2% au-dessus des attentes en topline (65.5 MdDKK, +24% à cc) et 9% au niveau de l’EBIT (31.9 MdDKK, +30% à cc). La franchise GLP-1 tirée par Ozempic (+65% à cc) maintient la cadence avec une hausse de part de marché dans sa franchise Diabète et une dynamique en volume positive (6% de hausse de prescriptions ...
- ABGSC Healthcare Research
- Morten Larsen
- Damien Choplain
- Martial Descoutures
GSK : Very good start to the year
>Q1 beat expectations - GSK reported Q1 sales (+4.4% vs consensus) and core EPS (+15.9% vs consensus) ahead of expectations. Sales were up 10% at cc (+6% GBP). All divisions turned in a good performance: Specialty Medicines (+12.8%, +1% vs css), Vaccines (+11.6%, +5.5% vs consensus) driven by Arexvy (£ 180m - launched in Q3 2023, in line) and Shingrix (+13.4%, +4.4% vs consensus) General Medicine declined less sharply than expected (-4.4%, +7.7% vs consensus). Core EB...
- Damien Choplain
- Martial Descoutures
GSK : Très bon début d’année - guidance relevée
>T1 supérieur aux attentes - GSK publie un T1 au-dessus des attentes au niveau des ventes (+4.4% vs css) et de son core EPS (+15.9% vs css). Les ventes ressortent en hausse de 10% tcc (+6% GBP). Notons une bonne performance de toutes les divisions : Specialty Medicines (+12.8%, +1% vs css), Vaccines (+11.6%, +5.5% vs css) tirée par Arexvy (+180 M£ - lancé au T3 23, en ligne) et Shingrix (+13.4%, +4.4% vs css) General Medicine décline moins fortement qu’attendu (-4.4%,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.